Tagged with MEA

UAE Genpharm is a Dubai-based regional company providing market access and marketing solutions for rare disease products in the MENA region. Co-Founders Karim Smaira and Kamel Ghammachi provide insights into the rare disease space in the region, explain how the company is positioning itself in the gene therapy arena and why…

UAE Mediclinic Middle East, the largest private healthcare group in the UAE, is betting on the continuum of care to continue thriving in a highly competitive market. CEO David Hadley explains the company’s presence in the country, with seven hospitals and 21 clinics, and provides insights into the UAE healthcare industry’s…

UAE Eli Lilly’s president and general manager for the SAMETA (South Asia, Middle East, Turkey, and Africa) region, José Antonio Alas, discusses the challenges attached to overseeing 70 countries and half of the world’s population, the main opportunities for Lilly’s diabetes and oncology portfolio in the region, and the importance of…

UAE Mundipharma, through its model of independent associated companies, is aiming to take the lead in the Middle East, Turkey & Africa markets through its continuous commitment to improving peoples’ lives. Ashraf Allam, regional VP for the META region, discusses his journey of building Mundipharma’s strong footprint in the region and…

UAE Vishnu Kalra, Janssen’s managing director for the GCC region, reflects on his 18-year career with Johnson & Johnson, including his perspective on the success factors behind the company’s strong growth in the region. Moreover, he highlights Janssen’s diversified portfolio across different therapeutic areas, with neuroscience, oncology, haematology, pulmonary arterial hypertension…

MEA These 10 corporations represent 37% of the MEA market by value. Novo Nordisk’s USD 635M growth is mainly driven by Norditropin (somatropin), Victoza (liraglutide) & Saxenda (liraglutide) which have grown at 60%, 18% and 190% PPG respectively. Hikma’s USD 497M growth has been the fastest due to Remox (amoxicillin) and…

UK Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and global leadership in clinical trials. To her, the UK has to maintain its core differentiators, such as a health technology…

UK Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how the company is looking at Brexit as a glass half full. Eisai views Brexit as an opportunity to bring with…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…

Switzerland Lupin’s EMEA President Thierry Volle explains that to fuel growth in the EMEA region, Lupin is investing heavily in transforming the business from a generics company into a specialty pharma player. Mr Volle, given your background in the innovative pharma sector, what was it that attracted you to join Lupin?…

Switzerland Santen’s Head of EMEA explains why the company established their new regional headquarters in Geneva, Switzerland and highlights the three key strategic pillars on which he bases the growth strategy for the region.   The immense talent present here contributes to the strategic value of the EMEA region, which we…

Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…